Stock LGND LIGAND PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Real-time Estimate Cboe BZX
Other stock markets
 11:51:15 2024-04-29 am EDT 		5-day change 1st Jan Change
70 USD -0.81% Intraday chart for Ligand Pharmaceuticals Incorporated +1.77% -2.35%
Apr. 08 Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference CI
Apr. 03 Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
BU
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K
PU
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
BU
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
AQ
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
BU
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
BU
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Ligand: Q4 Earnings Snapshot
AQ
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
BU
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
AQ
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
BU
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
BU
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
AQ
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
BU
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
BU
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
BU
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LGND Stock
  4. News Ligand Pharmaceuticals Incorporated
  5. Press Releases